or Try an Advanced Search...

    Transplant Rejection Stocks List

    Symbol Grade Name % Change
    CDNA B CareDx, Inc. -3.77
    ALKS F Alkermes plc 0.82
    BMY F Bristol-Myers Squibb Company 2.09
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Major
    Related Stock Lists: Biopharmaceutical Depressive Disorder Diabetes Hypertension Organic Chemistry Schizophrenia Alcohol Angina Atrial Fibrillation Atypical Antipsychotics Biopharmaceutical Products Blood Test Cachexia Cancer Treatment Chemotherapy Cholesterol Chronic Myeloid Leukemia Clinic Clinical Medicine Cocaine

    Related ETFs - A few ETFs which own one or more of the above listed Transplant Rejection stocks.

    Symbol Grade Name Weight
    FTXH D First Trust Nasdaq Pharmaceuticals ETF 7.02
    ARKG F ARK Genomic Revolution Multi-Sector ETF 5.66
    JFWD D Jacob Funds Inc. Jacob Forward ETF 4.91
    PSIL F AdvisorShares Psychedelics ETF 4.82
    MEDX D Horizon Kinetics Medical ETF 4.71
    View all Transplant Rejection ETFs...
    Compare ETFs
    Compare FTXH to PSIL Compare JFWD to PSIL Compare PSIL to MEDX

        Transplant Rejection Stocks Recent News

        Date Stock Title
        May 31 ALKS Why Is Alkermes (ALKS) Down 2.7% Since Last Earnings Report?
        May 31 BMY Bristol Myers Squibb’s Breyanzi gains FDA approval for lymphoma
        May 30 BMY Bristol-Myers Squibb's Options: A Look at What the Big Money is Thinking
        May 30 BMY Bristol Myers' Breyanzi gains additional indication for mantle cell lymphoma
        May 30 BMY Bristol Myers (BMY) Gets EC Nod for Opdivo Label Expansion
        May 30 CDNA AI Integration and Real-World Utility of CareDx Portfolio Highlighted in New Data at the 2024 American Transplant Congress
        May 29 ALKS Alkermes to Participate in Two Upcoming Investor Conferences
        May 29 BMY Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate
        May 29 BMY Bristol-Myers gets EU approval for Opdivo for bladder cancer
        May 29 BMY BMS secures another EC approval for Opdivo combination
        May 29 BMY BMS stakes $80m on Prothena’s neurodegenerative candidate
        May 29 CDNA CareDx Reiterates Position that it Does Not Infringe the ‘544 Patent, Injunction Motion is Irrelevant
        May 29 CDNA CareDx to Participate in Upcoming Investor Conferences
        May 29 BMY Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
        May 28 BMY ASPIRE: Our Commitment To Address Health Inequities in Low- and Middle-Income Countries
        May 28 ALKS Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024
        Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Major
        Related Stock Lists: Biopharmaceutical Depressive Disorder Diabetes Hypertension Organic Chemistry Schizophrenia Alcohol Angina Atrial Fibrillation Atypical Antipsychotics Biopharmaceutical Products Blood Test Cachexia Cancer Treatment Chemotherapy Cholesterol Chronic Myeloid Leukemia Clinic Clinical Medicine Cocaine
        Transplant Rejection

        Transplant rejection occurs when transplanted tissue is rejected by the recipient's immune system, which destroys the transplanted tissue. Transplant rejection can be lessened by determining the molecular similitude between donor and recipient and by use of immunosuppressant drugs after transplant.

        More about Transplant Rejection
        Browse All Tags